News

For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

17th Oct 12

Chairman's Address to 2012 Annual Gerneral Meeting.

Chairman's address to 2012 annual general meeting - 17 October 2012.

 

Read full media release - pdf
10th Oct 12

Presentation of Data at the North American Cystic Fibrosis Conference

Pharmaceutical company Pharmaxis (ASX: PXS) is pleased to announce that Bronchitol® is the subject of three presentations at the 26th annual North American Cystic Fibrosis Conference to be held in Orlando, Florida from October 10th – 13th.  These presentations focus on new analyses of patient subgroups in the Phase 3 clinical trials.

The abstracts are available on the NACF conference website at: https://www.nacfconference.org/

 

Read full media release - pdf
27th Sep 12

Pharmaxis Receives Maximum Extension of Term to Major European Patent

Pharmaceutical company Pharmaxis (ASX: PXS) is pleased to announce it has received notification from the German Patent Office that the European Patent for both Aridol® and Bronchitol® has been extended by five years.

The extension to the patent, through the granting of a Supplementary Protection Certificate (SPC) is for the maximum allowable period of 5 years which will see the Aridol and Bronchitol patent extended from 24th February 2015 to 23rd February 2020.

 

Read full media release - pdf